Focuses on developing therapies targeting telomeres for cancer and age-related diseases.
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company headquartered in Baltimore, Maryland, specializing in the development and commercialization of therapeutic treatments targeting human stem cells. The company's primary focus is on advancing TELOMIR-1, an innovative small molecule designed to serve as an oral therapeutic intervention for age-related inflammatory conditions. These conditions include hemochromatosis and osteoarthritis, as well as addressing health issues that may arise post-chemotherapy.
Formerly known as Metallo Therapies Inc., Telomir Pharmaceuticals underwent a name change in October 2022 to reflect its renewed focus and strategic direction in pharmaceutical innovation. Since its incorporation in 2021, the company has rapidly positioned itself as a key player in the field of therapeutic treatments for stem cell-related disorders.
Telomir Pharmaceuticals is committed to leveraging cutting-edge research and development to advance TELOMIR-1 and expand its pipeline of novel therapies. With a mission to address unmet medical needs through innovative science, the company aims to improve patient outcomes and enhance quality of life for individuals affected by these debilitating conditions.